Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766008 | 0.73 | ADRA2A (0.50) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL103158 | 0.73 | MAOB (0.63) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL30036439 | 0.73 | MAOB (0.63) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL17502945 | 0.72 | NPC1 (0.43) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL712885 | 0.72 | MAOB (0.49) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL30561833 | 0.70 | MAOB (0.55) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL2150499 | 0.69 | MAOB (0.59) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL4810005 | 0.69 | MAOB (0.46) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL5582544 | 0.68 | NPC1 (0.53) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL7909606 | 0.68 | NPC1 (0.45) | NPC1RAB9AMAPTMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-1313717-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7176224-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040138277-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
| EP-1313717-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016332-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138277-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | PPARA, PPARD, PPARG | NPC1 1199/4885RAB9A 3800/4885MAPT 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.